PTC Therapeutics' reported top line is dominated by episodic collaboration and licensing recognition, with revenue swinging from roughly $1.2B in 2025Q1 to $164.7M in 2025Q4, which suggests underlying commercial growth is not yet steady.
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue has been highly volatile, with quarterly gross margin ranging from 45.1% to 98.9% and operating margin swinging from -76.2% to 82.5%, indicating that one-time recognition rather than steady commercial growth drives reported results.
PTC Therapeutics issued full-year 2026 guidance projecting total product revenue of US$700 million to US$800 million, excluding Evrysdi royalty and collaboration revenue.
PTC Therapeutics reported positive 24-month interim results from the PIVOT-HD study, showing dose-dependent slowing of Huntington's disease progression and sustained reduction of mutant Huntingtin protein with votoplam.
An investment manager significantly increased their position in PTCT stock, adding 41,000 shares, as indicated by a recent SEC filing.
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Oct 29, 2026 | -$0.62-532.4% vs $0.14 | $358M+16.8% vs $306M |
Q3 2026 Jul 30, 2026 | $0.92+289.3% vs $0.24 | $361M+20.7% vs $299M |
Q2 2026 May 7, 2026 | -$0.03+93.3% vs -$0.45 | $273M+25.4% vs $217M |
Q1 2026 Feb 19, 2026 | -$1.67-695.2% vs -$0.21 | $165M-41.1% vs $279M |
PTC Therapeutics (PTCT) is rated Hold, bordering on Sell, with fair value estimated at $52/share versus a $59.97 current price. Sephience's strong launch drives growth, but legacy product declines offset gains; Q4 and 2027 results are key inflection points. PTCT's guidance has been consistently conservative, with actual quarterly sales repeatedly beating top-end forecasts.
WARREN, N.J., Nov. 3, 2026 /PRNewswire/ -- PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that its Board of Directors has authorized a share repurchase program under which PTC may repurchase up to $500 million of the Company's outstanding shares of common stock, subject to market conditions.
WARREN, N.J., Nov. 2, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that its executives will speak at the following conferences: Jefferies Global Healthcare Conference Monday, Nov. 16 at 11 a.m.
WARREN, N.J., Oct. 30, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Oct. 28, 2026, the company approved non-statutory stock options to purchase an aggregate of 9.620 shares of its common stock and 11,535 restricted stock units ("RSUs"), each representing the right to receive one share of its common stock upon vesting, to 13 new employees.
Benchmark PTCT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for PTC Therapeutics, Inc. (PTCT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $65.44 | $5.43B | -51.55 | 114.51% | -9.17% | — | — | |
| $17.82 | $1.88B | 127.93 | 15.58% | 0.75% | 1.04% | — | |
| $56.03 | $10.83B | -567.68 | 12.87% | -0.52% | -0.31% | — | |
| $15.43 | $1.52B | -3.01 | 20.13% | -71.78% | — | — | |
| $155.94 | $20.82B | 7.90 | 65.19% | 54.34% | 159.72% | — | |
| $21.23 | $3.64B | 10.28 | 11.87% | 30.13% | 28.03% | — |
PTC Therapeutics, Inc. (PTCT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
PTC Therapeutics, Inc. (PTCT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Oct 29, 2026·SEC
Jul 30, 2026·SEC
Jun 18, 2026·SEC
Get notified when PTCT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
PTC Therapeutics, Inc. (PTCT) stock FAQ — growth, dividends, profitability & financials explained
PTC Therapeutics, Inc. (PTCT) reported $1.16B in revenue over the trailing twelve months. Revenue was $1.73B in fiscal year 2025. That is 1649% more than the $99.0M of fiscal year 2011.
PTC Therapeutics, Inc. (PTCT) revenue fell by 35.1% over the trailing twelve months, compared with the twelve months before.
No. PTC Therapeutics, Inc. (PTCT) reported a net loss of $106.0M over the trailing twelve months.
PTC Therapeutics, Inc. (PTCT) had negative free cash flow of $38.0M over the trailing twelve months.
